Ignite Creation Date:
2024-05-06 @ 4:14 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04924179
Status:
UNKNOWN
Last Update Posted:
2022-08-17
First Post:
2021-06-03
Brief Title:
Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC
Sponsor:
Organization:
Huazhong University of Science and Technology